G1/25 – “Hydroponics”
Edward Rainsford discusses the Board of Appeal decision T697/22, a much-watched case that could have significant implications for future practice at the European Patent Office.
Read more
Emotional Perception: Time to Face the Music?
Ahead of the next chapter in the ongoing UK proceedings regarding the ”Emotional Perception” patent application (application number GB1904713.3), our experts re-cap the story so far and share hopes on what might happen next.
Read more
New UK IPO guidance on overly broad trade mark terms
Following the Supreme Court’s decision in SkyKick v Sky — on 27 June 2025, the UK IPO issued important guidance on how it will now approach trade mark applications — and it’s a significant shift. This article summarises what the new guidance means for trade mark applicants and businesses.
Read more
UK SEP/FRAND interim licence declarations – an exercise of the Court’s jurisdiction or of ‘judicial imperialism’?
Last week, the High Court issued its judgment on interim FRAND licences in Samsung v ZTE.
Read more
G1/24 Decision of the Enlarged Board of Appeal
The Enlarged Board of Appeal issued their decision in the case of G1/24 on 18 June 2025. Our experts discuss the relevance for IP professionals.
Read more
When can legitimate goods be modified and resold using the original trade mark?
This article examines the legal principles of trade mark exhaustion and explores how brand owners can manage their reputation after goods have been sold.
Read more
The power of organoids – advances in disease modelling research
In March 2025, the first Cambridge Human Organoid Symposium took place at Jesus College, Cambridge. Having attended, trainee patent attorney Oliver Herd shares the latest research findings presented.
Read more
Targeting the undruggable proteome with molecular glues
Recent patent and clinical trial activity highlights a rising global interest in molecular glue research to improve patient outcomes for cancer, neurodegenerative, and autoimmune disease treatments.
Read more
Patent filings in treatments for neurodegenerative disorders: a shift toward biotherapeutic innovation
This article explores a major shift in global patent filings for neurodegenerative disorder therapies over the past decade. Once dominated by big pharma’s small molecules, innovation is now increasingly led by SMEs developing biotherapeutics targeting root causes. This trend reflects rising interest in precision medicine and suggests progress toward more effective treatments beyond symptom management.
Read more
Optus v Apple – CoA increases FRAND licence to $500m ($700m with interest) in favour of Optus
In a judgment that further swings the pendulum back towards the UK being a 'SEP-owner-friendly' jurisdiction, the CoA has set the terms of the FRAND licence payable by Apple at a little over $700m ($500m + $200m interest).
Read more
IP audits – what are the benefits?
In this article, Senior Associate, Rachel Mercer, and Trainee Patent Attorney, Emma Lyons, explore the value of IP audits for businesses of all sizes. Discover how an audit can uncover hidden assets, support funding efforts, and strengthen your IP strategy. With the UKIPO’s updated ‘IP Advance’ scheme offering financial support to SMEs, now is an ideal time to assess and optimise your IP portfolio.
Read more
